Search

Your search keyword '"Lepage C"' showing total 871 results

Search Constraints

Start Over You searched for: Author "Lepage C" Remove constraint Author: "Lepage C"
871 results on '"Lepage C"'

Search Results

2. Annual cycle of Whitewinged Scoters (Melanitta fusca)in eastern North America: migratory phenology, population delineation, and connectivity

8. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

10. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)

11. Chimiothérapie par oxaliplatine normalisée à la quantité de masse maigre pour des cancers du côlon de stade III traités en adjuvant : impact sur les neurotoxicités à partir d’une étude randomisée multicentrique de phase II (LEANOX)

12. Sporadic non-functional neuroendocrine pancreatic incidentalomas (NF-NEI) ≤ 2 cm: risk of progression over 3 years. Results of the prospective multicenter French national study IPANEMA

13. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona

15. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

21. Comment différencier un ‘vrai’ d’un ‘faux’ VIPome : étude nationale multicentrique du GTE-ENDOCAN-RENATEN avec test d’interférence biologique

22. LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

23. LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial

25. 321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial

26. 502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

27. 1447P Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

29. 572P Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial

35. OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer

40. Non-Pharmaceutical Interventions for Self-Regulatory Failures in Adolescents Suffering from Externalizing Symptoms: A Scoping Review

41. 391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

42. LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

45. PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904)

46. A collaborative resource platform for non-human primate neuroimaging

47. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

49. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD

Catalog

Books, media, physical & digital resources